Haprolid Inhibits Tumor Growth of Hepatocellular Carcinoma through Rb/E2F and Akt/mTOR Inhibition.
Jun XingVikas BhuriaKhac Cuong BuiMai Ly Thi NguyenZexi HuChih-Jen HsiehKathrin WittsteinMarc StadlerLudwig WilkensJun LiMarkus KalessePrzemyslaw BozkoRuben R PlentzPublished in: Cancers (2020)
Our results show that haprolid inhibits the growth of HCC through dual inhibition of Rb/E2F and Akt/mTOR pathways. Therefore, haprolid might be considered as a new and promising candidate for the palliative therapy of HCC.